Are you a patient?
Click here
to learn more about Myopia.
About
Why Myopia?
Myopia In The News
Pipeline
Management
Press Releases
Contact
About
Why Myopia?
Myopia In The News
Pipeline
Management
Press Releases
Contact
Sydnexis is decreasing myopic progression in children.
Formulation Matters!
Our patented formulation is designed for comfort and efficacy.
See How
Sydnexis is decreasing myopic progression in children.
See How
A novel, stable, & comfortable topical eyedrop used once daily at bedtime.
See How
Treating Myopia with the STAR Study
A Phase 3 study to treat the progression of myopia in children.
Learn More
Are you a patient?
Learn more about Myopia & how to treat it.
Click Here
Latest News
Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access
Sydnexis Welcomes Erin Horn as Vice President, Head of Market Access
Read More
January 19, 2024
Sydnexis Welcomes Nick Ruth as Chief Commercial Officer
Sydnexis is excited to announce the appointment of Nick Ruth, MBA, as its Chief Commercial Officer.
Read More
August 30, 2023
Previous News
